Drug Profile
Research programme: GPCR modulators - Pfizer/Nxera Pharma
Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Heptares Therapeutics; Pfizer
- Developer Nxera Pharma; Pfizer
- Class Anti-inflammatories; Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Metabolic disorders